The Mirpuri Foundation supports groundbreaking research as a shareholder and investor of TTxD – Trained Therapeutix Discovery, Inc., the biotech company founded by Jean Boulle Medtech at the forefront of a unique immunotherapy strategy –, that is now testing its platform for a completely new approach for treating Acute Respiratory Distress Syndrome (“ARDS”), which could prove to be highly effective in saving the lives of Covid–19 patients.
TTxD’s proprietary technology is based on over a decade of research and development using bioengineering methods to produce nanobiologic therapeutics that can induce an immune response against tumors or dampen hyperinflammation after organ transplantation. TTxD has an established library of nanobiologic therapeutics relevant to many applications and potentially fatal diseases, including ARDS.
Under an exclusive license from the Icahn School of Medicine at Mount Sinai in New York and Radboud University Medical Center in the Netherlands, TTxD applies advanced bioengineering methods to develop nanobiologic therapeutics. Nanobiologics are materials constructed from molecular building blocks that our body produces naturally. The advantage of this approach is that nanobiologic therapy ‘hijacks’ natural mechanisms to regulate the immune system with materials that are inherently well tolerated by the body.
Developments:
As a shareholder and investor of TTxD, the Mirpuri Foundation notes the results of a clinical trial published in Cell showing that trained immunity through the use of BCG vaccination can reduce respiratory tract infections by 80% amongst elderly people including, potentially, COVID-19.
The Trial provides further evidence that BCG induces trained immunity responses and validates the approach followed by TTxD which uses advanced bioengineering methods to produce nanobiologic therapeutics based upon components of the BCG vaccine. The Trial was coordinated by Mihai G. Netea, founder and Chair of TTxD’s scientific advisory board and Professor of Experimental Internal Medicine at Radboud UMC. The Trial was a collaboration between the University of Athens Medical School, Radboud University Medical Center and the Life & Medical Sciences Institute, University of Bonn.
Various studies have shown that BCG vaccination can control the production of cytokines by the immune system to provide non-specific beneficial effects against infections. TTxD’s proprietary platform technology is based on over a decade of research and development. Under an exclusive license from the Icahn School of Medicine at Mount Sinai in New York and Radboud University Medical Center in the Netherlands, TTxD applies advanced bioengineering methods to develop nanobiologic therapeutics based upon the BCG vaccine. Nanobiologics are materials constructed from molecular building blocks that our body produces naturally. The advantage of this approach is that nanobiologic therapy modulates natural mechanisms to regulate the innate immune system with materials that are inherently well tolerated by the body.
The Mirpuri Foundation is a shareholder and investor of TTxD: Trained Therapeutix Discovery, Inc. (“TTxD”), an immunotherapy biotech company founded by Jean Boulle Therapeutics. Jean Boulle Medtech is involved in exploring and developing new technologies in a range of life saving areas of medicine.
More about this study here and here.
